

BIOLIFE SOLUTIONS INC  
Form 10QSB  
May 15, 2007

**UNITED STATES**  
**SECURITIES AND EXCHANGE COMMISSION**  
**WASHINGTON, DC 20549**

---

**FORM 10-QSB**

**(Mark One)**

x

**QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the quarterly period ended March 31, 2007**

..

**TRANSITION REPORT PURSUANT TO SECTION 12 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934**

**For the transition period from \_\_\_\_\_ to \_\_\_\_\_**

---

**0-18170**

(Commission File No.)

**BioLife Solutions, Inc.**

(Exact name of small business issuer as specified in its charter)

**Delaware**

**94-3076866**

(State or Other Jurisdiction of Incorporation)

(IRS Employer I.D. Number)

**11810 North Creek Parkway North**

**Bothell, WA 98011**

(Address of principal executive offices)

**(425) 402-1400**

(Registrant's telephone number, including area code)

Check whether the issuer (1) filed all reports required to be filed by Section 13 or 15(d) of the Exchange Act during the past 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes  No

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12G-2 of the Exchange Act).  
Yes  No

**69,606,520 shares of BioLife Solutions, Inc. Common Stock, par value \$.001 per share, were outstanding as of May 11, 2007**

Transitional Small Business Disclosure Format (check one). Yes  No .

**BioLife Solutions, Inc.**

**Form 10-QSB**

**Quarter Ended March 31, 2007**

**Index**

	Page No.
Part I. Financial Information	
Item 1. Financial Statements:	
Unaudited Balance Sheet at March 31, 2007	2
Unaudited Statements of Operations for the three month periods ended March 31, 2007 and March 31, 2006	3
Unaudited Statements of Cash Flows for the three month periods ended March 31, 2007 and March 31, 2006	4
Notes to Financial Statements	5-8
Item 2. Management's Discussion and Analysis	9-12
Item 3. Controls and Procedures.	12
Part II.	
Other Information	
Item 1. Legal Proceedings	13
Item 2. Unregistered Sale of Securities	13
Item 6. Exhibits	13
Signatures	14
Index to Exhibits	15



**Part I****Financial Information****Item 1. Financial Statements****BioLife Solutions, Inc.****Balance Sheet****(Unaudited)**

	<b>March 31, 2007</b>
<b><u>Assets</u></b>	
<b>Current assets</b>	
Cash and cash equivalents	\$ 288,677
Trade receivables, net of allowance for doubtful accounts	149,287
Inventories	63,813
Prepaid expenses and other current assets	81,668
<b>Total current assets</b>	<b>583,445</b>
<b>Property and equipment</b>	
Leasehold improvements	59,264
Furniture and computer equipment	54,736
Manufacturing and other equipment	174,760
<b>Subtotal</b>	<b>288,760</b>
Less: Accumulated depreciation and amortization	(197,014)
<b>Net property and equipment</b>	<b>91,746</b>
<b>Other assets</b>	
Deferred financing costs, net of amortization	71,875
<b>Total assets</b>	<b>\$ 747,066</b>
<b><u>Liabilities and Stockholders' Deficit</u></b>	
<b>Current liabilities</b>	
Accounts payable	\$ 136,390
Accounts payable - related parties	50,832
Accrued expenses	50,621
Accrued compensation	64,437
<b>Total current liabilities</b>	<b>302,280</b>

**Long term liabilities**

Promissory notes payable related parties **750,000**

**Total liabilities** **1,052,280**

**Commitments and contingencies**

**Stockholders deficit**

Common stock, \$0.001 par value, 100,000,000 shares  
 authorized, 69,606,520 shares issued and outstanding **69,607**

Additional paid-in capital **42,034,971**

Accumulated deficit **(42,407,509)**

**Subtotal** **(302,931)**

Stock subscriptions receivable **(2,283)**

**Total stockholders deficit** **(305,214)**

**Total liabilities and stockholders deficit** **\$ 747,066**

See notes to financial statements

**BioLife Solutions, Inc.****Statements of Operations****(Unaudited)**

	<b>Three Months Ended</b>	
	<b>March 31,</b>	
	<b>2007</b>	<b>2006</b>
<b>Revenue</b>		
Product sales	\$ 207,488	\$ 147,045
<b>Operating expenses</b>		
Cost of product sales	101,520	81,219
Sales and marketing	150,631	37,867
Research and development	37,557	4,280
General and administrative	503,175	232,799
<b>Total expenses</b>	<b>792,883</b>	<b>356,165</b>
<b>Operating loss</b>	<b>(585,395)</b>	<b>(209,120)</b>
<b>Other income (expense)</b>		
Interest income	2,368	901
Interest expense	(9,503)	(2,795)
Other income	1,000	-
<b>Total other income (expense)</b>	<b>(6,135)</b>	<b>(1,894)</b>
<b>Net loss</b>	<b>\$ (591,530)</b>	<b>\$ (211,014)</b>
<b>Total basic and diluted net loss</b>		
<b>per common share</b>	<b>\$ (0.01)</b>	<b>\$ (0.02)</b>
Basic and diluted weighted average common shares used to compute net loss per common share	<b>69,013,928</b>	<b>12,413,209</b>

See notes to financial statements



**BioLife Solutions, Inc.****Statements of Cash Flows****(Unaudited)****Three Months Ended  
March 31,****2007****2006****Cash flows from operating activities**

Net loss	\$ (591,530)	\$ (211,014)
----------	--------------	--------------

**Adjustments to reconcile net loss to net cash  
used in operating activities**

Depreciation and amortization	5,691	12,382
-------------------------------	-------	--------

Amortization of deferred financing costs	3,125	-
--	-------	---

Stock-based compensation	24,521	23,708
--------------------------	--------	--------

**Change in operating net assets and liabilities****(Increase) decrease in**

Trade receivables	(50,307)	(6,632)
-------------------	----------	---------

Inventories	28,938	22,078
-------------	--------	--------

Prepaid expenses and other current assets	(67,254)	(21,317)
---	----------	----------

**Increase (decrease) in**

Accounts payable	69,972	76,993
------------------	--------	--------

Accounts payable related parties	26,953	-
----------------------------------	--------	---

Accrued expenses	20,534	(45,736)
------------------	--------	----------

Accrued compensation	1,956	6,130
----------------------	-------	-------

<b>Net cash used in operating activities</b>	<b>(527,401)</b>	<b>(143,408)</b>
--	------------------	------------------

**Cash flows from investing activities**

Purchase of property and equipment	(52,661)	(3,844)
------------------------------------	----------	---------

<b>Net cash used in investing activities</b>	<b>(52,661)</b>	<b>(3,844)</b>
--	-----------------	----------------

**Cash flows from financing activities**

Decrease in restricted cash	190,837	-
-----------------------------	---------	---

Proceeds from promissory notes	750,000	-
--------------------------------	---------	---

Principal payments on notes payable	(197,477)	(6,980)
-------------------------------------	-----------	---------

Collection of stock subscriptions receivable	6,705	-
--	-------	---

<b>Net cash provided (used) by financing activities</b>	<b>750,065</b>	<b>(6,980)</b>
---	----------------	----------------

<b>Net increase (decrease) in cash</b>	<b>170,003</b>	<b>(154,232)</b>
--	----------------	------------------

<b>Cash - beginning of period</b>	<b>118,674</b>	185,095
<b>Cash - end of period</b>	<b>\$ 288,677</b>	\$ 30,863

**Non-cash investing and financing activities:**

The Company issued 833,332 shares of common stock as payment for \$75,000 in loan origination costs during the three months ended March 31, 2007.

See notes to financial statements

**BioLife Solutions, Inc.**

**Notes to Financial Statements**

**A.**

**General**

Incorporated in 1998 in the State of Delaware as a wholly owned subsidiary of Cryomedical Sciences, Inc. ( Cryomedical ), BioLife Solutions, Inc. ( BioLife or the Company ) develops, manufactures and markets patented hypothermic storage and cryopreservation solutions for cells, tissues, and organs. The Company's proprietary HypoThermosol® and CryoStor™ line of solutions are marketed directly to companies, labs and academic institutions engaged in research and commercial applications. BioLife's line of serum free and protein free preservation solutions are fully defined and formulated to reduce or prevent preservation-induced, delayed-onset cell damage and death. BioLife's platform enabling technology provides academic and clinical researchers significant improvement in post-thaw cell, tissue, and organ viability and function.

In May 2002, Cryomedical implemented a restructuring and recapitalization program designed to shift its focus away from cryosurgery toward addressing preservation and transportation needs in the biomedical marketplace. On June 25, 2002 the Company completed the sale of its cryosurgery product line and related intellectual property assets to Irvine, CA-based Endocare Inc., a public company. In the transaction, the Company transferred ownership of all of its cryosurgical installed base, inventory, and related intellectual property, in exchange for \$2.2 million in cash and 120,022 shares of Endocare restricted common stock. In conjunction with the sale of Cryomedical's cryosurgical assets, Cryomedical's Board of Directors also approved merging BioLife into Cryomedical and changing its name to BioLife Solutions, Inc. In September 2002, Cryomedical changed its name to BioLife Solutions, Inc. and began to trade under the new ticker symbol, BLFS on the OTCBB. Subsequent to the merger, the Company ceased to have any subsidiaries.

The Balance Sheet as of March 31, 2007, the Statements of Operations for the three month periods ended March 31, 2007 and 2006 and the Statements of Cash Flows for the three month periods ended March 31, 2007 and 2006 have been prepared without audit. In the opinion of management, all adjustments necessary to present fairly the financial position, results of operations and cash flows at March 31, 2007, and for the three month period then ended, have been recorded. All adjustments recorded were of a normal recurring nature.

Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles have been condensed or omitted. It is suggested that these financial statements be read in conjunction with the financial statements and notes thereto, included in the Company's Annual Report on Form 10-KSB for the year ended December 31, 2006.

The results of operations for the three month period ended March 31, 2007 are not necessarily indicative of the operating results anticipated for the full year.

**B.**

**Financial Condition**

At March 31, 2007, the Company had stockholders' deficit of approximately (\$305,000), a working capital surplus of approximately \$281,000 and cash used for operating activities for the three months ended March 31, 2007 was approximately (\$527,000). The Company has been unable to generate sufficient income from operations to meet its operating needs. This raises doubt about the Company's ability to continue as a going concern.

The Company believes it has sufficient funds to continue operations in the near term. Future capital requirements will depend on many factors, including the ability to market and sell the Company's product line, research and development programs, the scope and results of clinical trials, the time and costs involved in obtaining regulatory approvals, the costs involved in obtaining and enforcing patents or any litigation by third parties regarding intellectual property, the status of competitive products, the maintenance of the manufacturing

facility, the maintenance of sales and marketing capabilities, and the establishment of collaborative relationships with other parties.

These financial statements assume that the Company will be able to continue as a going concern. If the Company is unable to continue as a going concern, the Company may be unable to realize its assets and discharge its liabilities in the normal course of business. The financial statements do not include any adjustments relating to the recoverability and classification of recorded asset amounts nor to amounts and classification of liabilities that may be necessary should the Company be unable to continue as a going concern.

### **C. Income Taxes**

The Company adopted FASB Interpretation No. 48, *Accounting for Uncertainty in Income Taxes* an Interpretation of FASB Statement No. 109 (FIN 48) on January 1, 2007. FIN 48 clarifies the accounting and reporting for uncertainties in income tax law. This Interpretation prescribes a comprehensive model for the financial statement recognition, measurement, presentation and disclosure of uncertain tax positions taken or expected to be taken in income tax returns.

Adopting FIN 48 had no cumulative effect on tax reserves or retained earnings (deficit). Upon adoption, the Company had no liability for income taxes associated with uncertain tax positions.

The Company's policy is to include interest and penalties related to income tax liabilities in general and administrative expenses.

With limited exception, the Company is no longer subject to U.S. federal, state and local or non-U.S. income tax audits by taxing authorities for years through 2002. No income tax returns are currently under examination by any taxing authorities.

### **D.**

#### **Inventories**

Inventories consist of \$32,278 of finished product and \$31,535 of manufacturing materials at March 31, 2007.

### **E.**

#### **Promissory Notes Payable**

In February 2007, in an effort to secure additional capital, the Company borrowed \$750,000, represented by two promissory note agreements from two stockholders of the Company. Each Note, together with interest accrued thereon at the rate of 7% per annum (collectively, the *Conversion Amount*), shall become due and payable in one lump sum on the earlier of (a) the second anniversary of the date of such Note, (b) an Event of Default (as defined in

the Notes) or (c) sale, merger or change in control of the Company, as defined. In addition, if the Note is outstanding at the time of any bona fide equity financing of the Company of at least \$1,000,000 (excluding conversion of the Notes) (a Financing ), then the Note holder may convert the Note into that number of shares or units of the equity securities of the Company sold in the Financing ( New Equity Securities ) as is equal to the Conversion Amount divided by 85% of the per share or per unit purchase price of the New Equity Securities. The intrinsic value of the beneficial conversion feature at the commitment date of the notes was \$132,352. No value for the beneficial conversion feature has been recorded in these financial statements since the notes become convertible only upon the occurrence of a future event outside the control of the holders.

In connection with the issuance of the Notes, each Note holder received a loan origination fee equal to 10% of the principal amount of the Note, payable in shares of the Company s common stock based on the closing price of the shares on the OTCBB on the day preceding the date of issuance of the Note. The Company issued 833,332 shares of common stock as payment of the loan origination costs. The loan origination costs are being amortized over two years.

The Notes were issued pursuant to an exemption from registration under Regulation S of the Securities Act of 1933, as amended.

**F.**

**Stockholders Equity**

The fair value of options at the date of grant is determined under the Black-Scholes option-pricing model. During the three month period ended March 31, 2007, the following weighted-average assumptions were used:

<u>Assumptions</u>	<b>2007</b>
Risk-free rate	4.74%
Annual rate of dividends	-
Historical volatility	74.00%
Option life	6.1 years
Forfeiture rate	6.90%

There were no options awarded during the three month period ended March 31, 2006.

The following is a summary of stock option activity under the plans for the three month periods ending March 31, 2007 and 2006, and the status of stock options outstanding and available under the plans at March 31, 2007 and 2006:

	<b>Three Months Ended March 31, 2007</b>		<b>Three Months Ended March 31, 2006</b>	
	Shares	Wgtd. Avg. Exercise Price	Shares	Wgtd. Avg. Exercise Price
Outstanding at beginning of quarter	5,439,000	\$ 0.15	5,566,000	\$ 0.31
Granted	3,000,000	0.08	-	-
Exercised	-	-	-	-
Cancelled	(892,500)	(0.09)	-	-
Outstanding at end of quarter	7,546,500	\$ 0.13	5,566,000	\$ 0.31
Stock options exercisable at quarter end	2,431,500	\$ 0.23	3,511,000	\$ 0.41

Edgar Filing: BIOLIFE SOLUTIONS INC - Form 10QSB

The weighted average grant-date fair value of options awards was \$.06 per share during the three months ended March 31, 2007. There were no options awarded during the three month period ended March 31, 2006.

The total fair value of shares vested was \$1,476 and \$0 for the three month periods ended March 31, 2007 and 2006, respectively.

The following table summarizes information about stock options outstanding at March 31, 2007:

<b>Exercise Prices</b>	<b>Number Outstanding at March 31, 2007</b>	<b>Weighted Average Remaining Contractual Life</b>	<b>Weighted Average Exercise Price</b>
0.07	1,725,000	9.38	\$ 0.07
0.08	4,362,500	9.44	\$ 0.08
0.085	500,000	9.08	\$ 0.085
0.25	750,000	5.01	\$ 0.25
1.25	209,000	1.64	\$ 1.25





ordered to cease and desist and take appropriate action, such as reinstatement. The Division of Human Rights may award money damages, including back pay and compensatory damages for mental pain and suffering. The Company does not believe there is any merit to such complaint and is vigorously defending its position.

**I.**

**Reclassifications**

Certain March 2006 amounts have been reclassified to conform to the March 2007 presentation. The reclassifications had no material effect on operations.

**J.**

**Subsequent Event**

Although it has not been served with a summons and complaint, the Company is aware that John G. Baust, the Company's former Chief Executive Officer and Chief Scientific Officer, filed a complaint on April 6, 2007 in the New York State Supreme Court, County of Tioga, against the Company seeking, among other things, damages under his employment agreement to be determined upon trial of the action plus attorneys' fees, a declaratory judgment that he did not breach his fiduciary duties to the Company, and that his covenant not to compete is void as against public policy or unenforceable as a matter of law, and to enjoin the Company from commencing an action against him in Delaware courts seeking damages for breaches of his fiduciary obligations to the Company. The Company does not believe there is any merit to such lawsuit and, if need be, intends to defend the same vigorously.



## **Item 2. Management's Discussion and Analysis**

The following discussion should be read in conjunction with the Company's financial statements and notes thereto set forth elsewhere herein.

Derived from the Company's in depth know-how and understanding of the cellular molecular response to cold temperature and methods to mitigate related harmful effects, BioLife has pioneered the next generation of preservation solutions designed to maintain the viability and health of cellular matter and tissues during freezing, transportation and storage. Based on the Company's proprietary, bio-packaging technology and a patented understanding of the mechanism of cellular damage and death, these products enable the biotechnology and medical community to address a growing problem that exists today. The expanding practices of cell and gene therapy, cord blood banking, organ transplantation, toxicity testing, and drug discovery has created a need for products that ensure the biological viability of mammalian cell and tissue material during transportation, storage and following preservation. The Company believes that the HypoThermosol® and CryoStor™ products it is selling today are a significant step forward in meeting these needs.

The Company's line of serum free and protein free preservation solutions are fully defined and formulated to reduce or prevent preservation-induced, delayed-onset cell damage and death. BioLife's platform enabling technology provides academic and clinical researchers significant improvement in post-thaw cell, tissue, and organ viability and function.

BioLife has entered into agreements with several emerging biotechnology companies engaged in the research and commercialization of cell and gene therapy technology.

The Company currently markets its HypoThermosol® and CryoStor™ line of solutions to companies, laboratories and academic institutions engaged in research and clinical applications.

### **Results of Operations (three month period ended March 31, 2007 compared to the three month period ended March 31, 2006)**

#### **Revenue**

Product sales for the quarter ended March 31, 2007 increased \$60,443, or 41%, to \$207,488, compared to \$147,045 for the quarter ended March 31, 2006. This increase is due to increased sales and marketing efforts as well as the increased use of BioLife products by several emerging and established companies engaged in commercializing new cellular-based therapies to treat cancer, heart disease, HIV and skin and bone disorders.

### **Cost of product sales**

Cost of product sales for the quarter ended March 31, 2007 increased \$20,301, or 25%, to \$101,520, compared to \$81,219 for the quarter ended March 31, 2006. This increase is primarily the result of increased production costs associated with the increase in product sales.

### **Sales and marketing expenses**

For the quarter ended March 31, 2007, sales and marketing expenses increased \$112,764, or 298%, to \$150,631, compared to \$37,867 for the quarter ended March 31, 2006. The increase in sales and marketing expense was due to increased sales and marketing activities such as tradeshows, advertising, travel, and supplies as well as the addition of salaries and commissions for two sales employees, including the Vice President of Sales.

### **Research and development expenses**

Expenses relating to research and development for the quarter ended March 31, 2007 increased \$33,277, or 778%, to \$37,557, compared to \$4,280 for the quarter ended March 31, 2006. This increase was due to contracted research payments and additional legal fees related to Company patents.

### **General and administrative expenses**

For the quarter ended March 31, 2007, general and administrative expenses increased \$270,376, or 116%, to \$503,175, compared to \$232,799 for the quarter ended March 31, 2006. Notable increases in general and administration expenses include an increase in professional fees of approximately \$135,000 from the first quarter of 2006 to the first quarter of 2007 as a result of increased legal fees related to litigation filed against the Company in 2007 and the outsourcing of the internal accounting function. Compensation expenses increased approximately \$73,000 due to the hiring of additional employees, an increase in bonuses in 2007 of \$27,000 and the payment of directors fees in 2007 for which no compensation policy existed in 2006. Travel expenses also increased approximately \$24,000 from the first quarter of 2006 to the first quarter of 2007 due to additional travel by the management team. Commercial and directors and officers insurance expenses increased approximately \$12,000 due to an increase in coverage limits.

### **Interest expense**

For the quarter ended March 31, 2007, interest expense was \$9,503. For the quarter ended March 31, 2006, interest expense was \$2,795. This increase is primarily the result of interest accrued on \$750,000 in promissory notes which were issued in February 2007.

### **Operating expenses and net loss**

For the quarter ended March 31, 2007, operating expenses (excluding product costs) increased \$416,417, or 151%, to \$691,363, compared to \$274,946 for the quarter ended March 31, 2006. The Company reported a net loss of (\$591,530) for the quarter ended March 31, 2007, compared to a net loss of (\$211,014) for the quarter ended March 31, 2006.

### **Liquidity and Capital Resources**

At March 31, 2007, the Company had cash and cash equivalents of \$288,677, compared to cash and cash equivalents of \$30,863 at March 31, 2006. At March 31, 2007, the Company had a working capital surplus of \$281,165, compared to a working capital deficit of (\$12,401) at March 31, 2006.

During the three months ended March 31, 2007, the Company generated approximately \$207,000 in product sales, representing a 41% increase over product sales for the three months ended March 31, 2006. While the increasing product sales appear promising, the Company has been unable to support its operations solely from revenue generated

from product sales.

In February 2007, in an effort to secure additional capital, the Company borrowed \$750,000, represented by two promissory note agreements from two stockholders of the Company. Each Note, together with interest accrued thereon at the rate of 7% per annum (collectively, the Conversion Amount), shall become due and payable in one lump sum on the earlier of (a) the second anniversary of the date of such Note, or (b) an Event of Default (as defined in the Notes). In addition, if the Note is outstanding at the time of any bona fide equity financing of the Company of at least \$1,000,000 (excluding conversion of the Notes) (a Financing), then the Note holder may convert the Note into that number of shares or units of the equity securities of the Company sold in the Financing (New Equity Securities) as is equal to the Conversion Amount divided by 85% of the per share or per unit purchase price of the New Equity Securities. In connection with the issuance of the Notes, each Note holder received a loan origination fee equal to 10% of the principal amount of the Note, payable in shares of the Company's common stock based on the closing price of the shares on the OTCBB on the day preceding the date of issuance of the Note. The Notes were issued pursuant to an exemption from registration under Regulation S of the Securities Act of 1933, as amended.

During the three month period ended March 31, 2007, net cash used in operating activities was approximately \$527,000, compared to net cash used in operating activities of approximately \$143,000 for the three month

period ended March 31, 2006. The use of cash is indicative of the Company's lack of sufficient sales to support operations.

During the three month period ended March 31, 2007, net cash used in investing activities was approximately \$53,000, compared to net cash used in investing activities of approximately \$4,000 for the three month period ended March 31, 2006. The use of cash resulted from purchases of property and equipment.

During the three month period ended March 31, 2007, net cash provided by financing activities was approximately \$750,000 compared to net cash used by financing activities of \$7,000 for the three month period ended March 31, 2006. Cash provided during the three month period March 31, 2007 resulted primarily from the issuance of promissory notes. Cash used during the three month period ended March 31, 2006 resulted from principal payments on a loan which was paid in full in January 2007 using restricted cash received in an insurance claim.

The Company believes it has sufficient funds to continue operations in the near term. Future capital requirements will depend on many factors, including the ability to market and sell our product line, research and development programs, the scope and results of clinical trials, the time and costs involved in obtaining regulatory approvals, the costs involved in obtaining and enforcing patents or any litigation by third parties regarding intellectual property, the status of competitive products, the maintenance of our manufacturing facility, the maintenance of sales and marketing capabilities, and the establishment of collaborative relationships with other parties.

### **Critical Accounting Policies and Estimates**

The Company's discussion and analysis of its financial condition and results of operations are based upon its financial statements, which have been prepared in accordance with accounting principles generally accepted in the United States. The preparation of these financial statements requires the Company to make estimates and judgments that affect the reported amounts of assets and liabilities, revenues and expenses and related disclosures. On an ongoing basis, the Company evaluates estimates, including those related to bad debts, inventories, fixed assets, income taxes, contingencies and litigation. The Company bases its estimates on historical experience and on various other assumptions that are believed to be reasonable under the circumstances, the results of which form the basis of the Company's judgments on the carrying value of assets and liabilities. Actual results may differ from these estimates under different assumptions or conditions.

The Company believes that following accounting policies involves more significant judgments and estimates in the preparation of the financial statements. The Company maintains an allowance for doubtful accounts for estimated losses that may result from the inability of its customers to make payments. If the financial condition of the Company's customers were to deteriorate, resulting in their inability to make payments, the Company may be required to make additional allowances. The Company writes down inventory for estimated obsolete or unmarketable inventory to the lower of cost or market based on assumptions of future demand. If the actual demand and market conditions are less favorable than projected, additional write-downs may be required.



### **Contract Obligations**

The Company leases equipment as lessee, under an operating lease expiring in November 2011. The lease requires monthly payments of \$337.

In November 2006, BioLife renewed an original 3-year lease for a one year term with Field Afar Properties, LLC whereby BioLife leases 6,161 square feet of office, laboratory, and manufacturing space in Owego, NY at a rental rate of \$6,200 per month. John G. Baust, the Company's former Chief Executive Officer and Chief Scientific Officer is a member of Field Afar Properties, LLC.

In March 2007, the Company signed a lease whereby BioLife leases 2,783 square feet of office and laboratory space in Bothell, WA at a rental rate of \$3,500 per month. The lease does not have an expiration date.

**Item 3.**

**Controls and Procedures**

At the end of the period covered by this Quarterly Report on Form 10-QSB, the Company carried out an evaluation, under the supervision and with the participation of the Company's management, including the CEO/CFO, of the effectiveness of the design and operation of the Company's disclosure controls and procedures pursuant to Exchange Act Rule 13a-15. Based upon that evaluation, the Company's CEO/CFO concluded that the Company's disclosure controls and procedures are effective in timely alerting him to material information relating to the Company required to be included in the Company's periodic SEC filings and are designed to ensure that information required to be disclosed by the Company in the reports it files or submits under the Exchange Act is recorded, processed, summarized and reported within the time permitted as specified by the rules and forms.

There were no significant changes in the Company's internal control over financial reporting during the quarterly period ended March 31, 2007 that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.

## Part II Other Information

### Item 1. Legal Proceedings

On February 7, 2007, a former employee of the Company filed a complaint in the New York State Supreme Court, County of Broome, against the Company alleging a breach of an employment agreement and seeking damages of up to \$300,000 plus attorneys' fees. The Company does not believe there is any merit to such lawsuit and is vigorously defending its position.

On or about March 21, 2007, Christine Baust, a former employee of the Company and daughter of John G. Baust, the Company's former Chief Executive Officer and Chief Scientific Officer, filed a complaint with the State of New York, Division of Human Rights alleging unlawful discrimination practices against the Company based on wrongful termination due to disability, and gender and sexual harassment. If discrimination is found, the Company would be ordered to cease and desist and take appropriate action, such as reinstatement. The Division of Human Rights may award money damages, including back pay and compensatory damages for mental pain and suffering. The Company does not believe there is any merit to such complaint and is vigorously defending its position.

Although it has not been served with a summons and complaint, the Company is aware that John G. Baust, the Company's former Chief Executive Officer and Chief Scientific Officer, filed a complaint on April 6, 2007 in the New York State Supreme Court, County of Tioga, against the Company seeking, among other things, damages under his employment agreement to be determined upon trial of the action plus attorneys' fees, a declaratory judgment that he did not breach his fiduciary duties to the Company, and that his covenant not to compete is void as against public policy or unenforceable as a matter of law, and to enjoin the Company from commencing an action against him in Delaware courts seeking damages for breaches of his fiduciary obligations to the Company. The Company does not believe there is any merit to such lawsuit and, if need be, intends to defend the same vigorously.

### Item 2. Unregistered Sale of Securities

In February 2007, in an effort to secure additional capital, the Company borrowed \$750,000, represented by two promissory note agreements from two stockholders of the Company. Each Note, together with interest accrued thereon at the rate of 7% per annum (collectively, the Conversion Amount), shall become due and payable in one lump sum on the earlier of (a) the second anniversary of the date of such Note, (b) an Event of Default (as defined in the Notes) or (c) sale, merger or change in control of the Company, as defined. In addition, if the Note is outstanding at the time of any bona fide equity financing of the Company of at least \$1,000,000 (excluding conversion of the Notes) (a Financing), then the Note holder may convert the Note into that number of shares or units of the equity securities of the Company sold in the Financing (New Equity Securities) as is equal to the Conversion Amount divided by 85% of the per share or per unit purchase price of the New Equity Securities. The Notes were issued pursuant to an exemption from registration under Regulation S of the Securities Act of 1933, as amended.

**Item 6.**

**Exhibits**

See accompanying Index to Exhibits included after the signature page of this report for a list of the exhibits filed or furnished with this report.

**SIGNATURES**

In accordance with the requirements of the Exchange Act, the registrant caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

**BioLife Solutions, Inc.**

Date: May 15, 2007

By: /s/ Michael Rice  
Michael Rice  
President and Chief Executive Officer  
(Principal Executive Officer)



**INDEX TO EXHIBITS**

Exhibit No.

Description

31.1

Certification pursuant to Section 302 of the Sarbanes-Oxley Act of 2002

32.1

Certification pursuant to Section 906 of the Sarbanes-Oxley Act of 2002